Marinus Pharmaceuticals (MRNS) said late Tuesday it secured a new patent from the US Patent and Trademark Office for Ztalmy, or ganaxolone, oral titration regimens covering the treatment of various epilepsy disorders.
The patent is scheduled to expire in September 2042, the company said.
Marinus shares were up 5.2% in after-hours activity.
Price: 1.8300, Change: +0.09, Percent Change: +5.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.